Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018862 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 489
- Enrollment target
NCT01018862 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 489 participants.
The verdict
NCT01018862, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 489 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of an Investigational use of an allergy medication (MP03-33) used to treat perennial allergic rhinitis (PAR) to placebo (a nasal spray that contains no medicine). In addition, the study will also compare the safety and effectiveness of an investigational use of another allergy medication (MP03-36) used to treat perennial allergic rhinitis to placebo.
Interventions
- DRUG Placebo
- DRUG Azelastine hydrochloride nasal spray 0.15%
- DRUG Azelastine hydrochloride nasal spray 0.10%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 489 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01018862
The ClinicalTrials.gov registry entry for NCT01018862 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 489 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meda Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01018862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01018862 about?
NCT01018862 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis". The purpose of this study is to compare the effectiveness of an Investigational use of an allergy medication (MP03-33) used to treat perennial allergic rhinitis (PAR) to placebo (a nasal spray that contains no medicine). In addition, the study will also compare the safety and effectiveness of an inv...
What is the current status of trial NCT01018862?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 489 participants. The study started on 2009-11. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01018862?
The interventions under investigation include: Placebo (DRUG), Azelastine hydrochloride nasal spray 0.15% (DRUG), Azelastine hydrochloride nasal spray 0.10% (DRUG).
Who is sponsoring clinical trial NCT01018862?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.